Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

The Effect of STAS Positivity in Lung Cancer

View through CrossRef
Abstract Aim of study: The spread through air spaces (STAS) phenomenon, which describes the presence of tumor cells in the air spaces of lung cancer, has been associated with an increased risk of local recurrence. We performed retrospective analyses to examine the presence of STAS and to evaluate its clinical results and its relationship with clinicopathological parameters. Materials and Methods: A total of 149 surgically resected lung cancer cases were analyzed retrospectively. Detailed analyses were performed on demographic- radiological-clinical-histological features. Results: The mean age of the patients was 63 (IQR = 11; range, 22–81), among whom 31 were female and 118 were male. The incidence of STAS was not different between the histological groups (p = 0.427). There was no difference between SUVmax value in STAS-positive and negative patients (p = 0.970). The recurrence rate, survival, and median tumor size were not different from each other in the STAS-positive and STAS-negative groups (p = 1,000, p = 0.086, p = 0.292, respectively). Conclusion: STAS is an independent risk factor for poor prognosis. Therefore, it may be possible to provide more personalized information by using clinicopathological markers that will facilitate preoperative prediction of STAS presence.
Title: The Effect of STAS Positivity in Lung Cancer
Description:
Abstract Aim of study: The spread through air spaces (STAS) phenomenon, which describes the presence of tumor cells in the air spaces of lung cancer, has been associated with an increased risk of local recurrence.
We performed retrospective analyses to examine the presence of STAS and to evaluate its clinical results and its relationship with clinicopathological parameters.
Materials and Methods: A total of 149 surgically resected lung cancer cases were analyzed retrospectively.
Detailed analyses were performed on demographic- radiological-clinical-histological features.
Results: The mean age of the patients was 63 (IQR = 11; range, 22–81), among whom 31 were female and 118 were male.
The incidence of STAS was not different between the histological groups (p = 0.
427).
There was no difference between SUVmax value in STAS-positive and negative patients (p = 0.
970).
The recurrence rate, survival, and median tumor size were not different from each other in the STAS-positive and STAS-negative groups (p = 1,000, p = 0.
086, p = 0.
292, respectively).
Conclusion: STAS is an independent risk factor for poor prognosis.
Therefore, it may be possible to provide more personalized information by using clinicopathological markers that will facilitate preoperative prediction of STAS presence.

Related Results

Platforming positivity: Young people's negotiations of sex and body positivity in digital and everyday life
Platforming positivity: Young people's negotiations of sex and body positivity in digital and everyday life
<p><strong>Sex positivity has roots in liberatory, feminist sexual politics and the movement has gained cultural momentum in recent years. In the context of #MeToo, the...
Multimodal CT Model: Enhancing Lung Cancer STAS Prediction vs. Unimodal CT
Multimodal CT Model: Enhancing Lung Cancer STAS Prediction vs. Unimodal CT
Abstract Background Lung cancer is one of the leading causes of cancer-related death worldwide. Tumor spread through air spaces...
Abstract SY38-02: Clinical investigations of obesity in cancer: BMI and other confounders
Abstract SY38-02: Clinical investigations of obesity in cancer: BMI and other confounders
Abstract Obesity has been linked with increased incidence and worse outcomes of at least 13 human cancers. For other cancers, our understanding of their relationship...
Abstract 1345: Evidence for genetic mediation of lung cancer through hay fever.
Abstract 1345: Evidence for genetic mediation of lung cancer through hay fever.
Abstract Introduction: In the past decade, advances in genetics have led to the discovery of numerous lung cancer susceptibility variants. The majority of these vari...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top